Fiona McPhee

9.7k total citations · 2 hit papers
98 papers, 3.8k citations indexed

About

Fiona McPhee is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Fiona McPhee has authored 98 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Hepatology, 54 papers in Epidemiology and 37 papers in Infectious Diseases. Recurrent topics in Fiona McPhee's work include Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (40 papers) and HIV/AIDS drug development and treatment (37 papers). Fiona McPhee is often cited by papers focused on Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (40 papers) and HIV/AIDS drug development and treatment (37 papers). Fiona McPhee collaborates with scholars based in United States, Germany and Italy. Fiona McPhee's co-authors include Eric Hughes, Dennis Hernandez, Hiroki Ishikawa, Kazuaki Chayama, Hiromitsu Kumada, Timothy Eley, David Gardiner, Yoshiyasu Karino, Joji Toyota and Megan Wind‐Rotolo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Fiona McPhee

94 papers receiving 3.8k citations

Hit Papers

Preliminary Study of Two Antiviral Agents for Hepatitis C... 2012 2026 2016 2021 2012 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
    2012 454 citations Anna S. Lok, David Gardiner et al. profile →
  2. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
    2016 331 citations Fiona McPhee, Eric Hughes et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fiona McPhee United States 29 3.2k 2.8k 1.2k 351 324 98 3.8k
Edward Tam United States 38 5.8k 1.8× 5.2k 1.9× 2.1k 1.8× 437 1.2× 274 0.8× 103 7.1k
Oliver Lenz Belgium 32 4.0k 1.3× 3.6k 1.3× 1.3k 1.1× 305 0.9× 347 1.1× 111 4.4k
Fernando Lopes Gonçales Brazil 15 5.7k 1.8× 5.0k 1.8× 757 0.6× 260 0.7× 563 1.7× 42 6.1k
Robert Reindollar United States 17 6.7k 2.1× 5.9k 2.1× 902 0.8× 329 0.9× 679 2.1× 34 7.2k
Nathalie Boyer France 43 6.3k 2.0× 6.2k 2.2× 554 0.5× 359 1.0× 620 1.9× 115 7.1k
Jonathan McCone United States 12 3.5k 1.1× 3.1k 1.1× 700 0.6× 164 0.5× 355 1.1× 20 3.7k
E. Jenny Heathcote Canada 33 7.2k 2.3× 7.1k 2.5× 895 0.8× 247 0.7× 289 0.9× 66 8.0k
Hadas Dvory‐Sobol United States 31 2.2k 0.7× 2.0k 0.7× 1.0k 0.9× 356 1.0× 135 0.4× 98 3.1k
Eric Hughes United States 26 1.8k 0.6× 1.7k 0.6× 575 0.5× 563 1.6× 212 0.7× 62 2.9k
Teresa I. Ng United States 26 1.1k 0.4× 1.4k 0.5× 661 0.6× 230 0.7× 95 0.3× 59 2.0k

Countries citing papers authored by Fiona McPhee

Since Specialization
Citations

This map shows the geographic impact of Fiona McPhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona McPhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona McPhee more than expected).

Fields of papers citing papers by Fiona McPhee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona McPhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona McPhee. The network helps show where Fiona McPhee may publish in the future.

Co-authorship network of co-authors of Fiona McPhee

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona McPhee. A scholar is included among the top collaborators of Fiona McPhee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona McPhee. Fiona McPhee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salichos, Leonidas, Chiara Taibi, Gianpiero D’Offizi, et al.. (2025). Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients. Biomedicines. 13(2). 280–280. 1 indexed citations
2.
Salichos, Leonidas, Claudia Minosse, Ubaldo Visco‐Comandini, et al.. (2023). Phylogenetic and Phylodynamic Analysis of Delta Strains Circulating in Italy. Viruses. 15(9). 1791–1791. 4 indexed citations
3.
Minosse, Claudia, Cesare Ernesto Maria Gruber, Martina Rueca, et al.. (2021). Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses. 13(6). 1151–1151. 7 indexed citations
4.
Hernandez, Dennis, Fei Yu, Xin Huang, et al.. (2016). Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Advances in Therapy. 33(7). 1169–1179. 16 indexed citations
5.
Bartolini, Barbara, Raffaella Lionetti, Emanuela Giombini, et al.. (2015). Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: A case study using ultra deep pyrosequencing. Journal of Clinical Virology. 66. 38–43. 11 indexed citations
6.
Zhou, Nannan, et al.. (2015). Lethality of PAK3 and SGK2 shRNAs to Human Papillomavirus Positive Cervical Cancer Cells Is Independent of PAK3 and SGK2 Knockdown. PLoS ONE. 10(1). e0117357–e0117357. 7 indexed citations
7.
8.
McPhee, Fiona, Yoshiyuki Suzuki, Joji Toyota, et al.. (2015). High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. Advances in Therapy. 32(7). 637–649. 51 indexed citations
9.
McPhee, Fiona, et al.. (2014). Endogenous IFNλ in Viral Hepatitis Patients. Journal of Interferon & Cytokine Research. 34(7). 552–556. 7 indexed citations
10.
Bronowicki, Jean–Pierre, Vlad Ratziu, Adrián Gadano, et al.. (2014). Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology. 61(6). 1220–1227. 21 indexed citations
11.
Lok, Anna S., David Gardiner, Christophe Hézode, et al.. (2013). Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Journal of Hepatology. 60(3). 490–499. 111 indexed citations
12.
McPhee, Fiona, Dennis Hernandez, Fei Yu, et al.. (2013). Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir. Hepatology. 58(3). 902–911. 98 indexed citations
13.
14.
Friborg, Jacques, et al.. (2013). Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. Virology. 444(1-2). 384–393. 2 indexed citations
15.
Karino, Yoshiyasu, Joji Toyota, Kenji Ikeda, et al.. (2012). Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. Journal of Hepatology. 58(4). 646–654. 134 indexed citations
16.
Suzuki, Yoshiyuki, Kenji Ikeda, Fumitaka Suzuki, et al.. (2012). Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology. 58(4). 655–662. 179 indexed citations
17.
Craik, Charles S., et al.. (1998). Engineering Catalytically Defective Forms of HIV Protease to Modulate Its Activity. Advances in experimental medicine and biology. 436. 31–39.
18.
Rutenber, Earl, James J. De Voss, Lucas R. Hoffman, et al.. (1997). The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease. Bioorganic & Medicinal Chemistry. 5(7). 1311–1320. 8 indexed citations
19.
Rutenber, Earl, et al.. (1996). A new class of HIV-1 protease inhibitor: The crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere. Bioorganic & Medicinal Chemistry. 4(9). 1545–1558. 21 indexed citations
20.
Kandolf, Reinhard, Karin Klingel, Roland Zell, et al.. (1993). Molecular Mechanisms in the Pathogenesis of Enteroviral Heart Disease: Acute and Persistent Infections. Clinical Immunology and Immunopathology. 68(2). 153–158. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward Tam Breakdown of academic impact, for papers by Oliver Lenz Breakdown of academic impact, for papers by Fernando Lopes Gonçales Breakdown of academic impact, for papers by Robert Reindollar Breakdown of academic impact, for papers by Nathalie Boyer Breakdown of academic impact, for papers by Jonathan McCone Breakdown of academic impact, for papers by E. Jenny Heathcote Breakdown of academic impact, for papers by Hadas Dvory‐Sobol Breakdown of academic impact, for papers by Eric Hughes Breakdown of academic impact, for papers by Teresa I. Ng
Rankless by CCL
2026